1. |
Noguchi M, Koyasaki N, Ohta N, et al. Cerb B2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph nodepositive breast cancer. Cancer, 1992; 69(13)∶2953.
|
2. |
Berchuck A, Kamel A, Whitaker R, et al. Overexpression of Her2/new is associated with poor survival in advanced epithelial ovarian cancer. Cancer Research, 1990; 50(13)∶4087.
|
3. |
Allred DC, Clark GM, Molina R, et al. Overexpression of Her2/new and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 1992; 23(9)∶974.
|
4. |
Porter PL, Garcia R, Moe R, et al. Cerb B2 oncogene protein in situ and invasive lobular breast neoplasia. Cancer, 1991; 68(2)∶331.
|
5. |
Wright C, Nicholson S, Angus B, et al. Relationship Cerb B2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer, 1992; 65(1)∶118.
|
6. |
Vaughb JP, Stekler J, Demirdji S, et al. Inhibition of the Cerb B2 tyrisne kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisence oligonucleotides. Nucleic Acids Res, 1996; 24(3)∶4558.
|
7. |
Visscher DW, Wallis T, Awussah S, et al. Evaluation of myc and chromosome δ copy number in breast carcinoma by interphase cytogenetics. Egenes Cgromosomes Cancer, 1997; 18(1)∶1.
|
8. |
Lindlom A, Skoog L, Rotstein S, et al. Loss of Heterozygosity in familial breast carcinomas carcinogenesis. Cancer Research, 1993; 53(18)∶4356.
|
9. |
Alan H. Signal transduction through small GTPasesa tale of two GAPs. Cell, 1992; 69(3)∶389.
|
10. |
Weinbery RA. Oncogenes, antioncogenes, and the moleeular bases of multistep. Cancer Research, 1989; 49(11)∶3713.
|
11. |
Cropps CS, Lidereau R, Leone A, et al. NME1 protein expression and loss of heterozygosity mutations in primary haman breast tumors. Journal of the National Cancer Institute, 1994; 86(15)∶1167.
|
12. |
顾学文,陶晓钰,陈月香. nm23基因在人乳腺癌中的表达及与淋巴结转移的关系.实用癌症杂志, 1997; 12(1)∶9.
|
13. |
王川,张祥福,杨发端等. nm23在乳腺癌中的表达及其预后意义.福建医学院学报, 1995; 29(3)∶236.
|
14. |
Mudenda B, Green JA, Breen B, et al. The relationship between serus p53 autoantibodies and characteristics of human breast cancer. Br J Cancer, 1994; 69(6)∶1115.
|
15. |
蔡永东,武正英,王乐.乳腺癌中抗癌基因p53突变及其临床预后.实用癌症杂志,1997; 12(2)∶117.
|
16. |
Vander KK, Rookus MA, Peterse HL, et al. p53 protein overexpression in relation to risk factors for breast cancer. Eridemiol, 1996; 144(10)∶924.
|
17. |
Silviastrini R, Veneronis, Diadone MG, et al. The bcl2 protein: a prognostic indicator strongly related to p53 protein in lymph nodenegative breast cancer patients. J Natl Cancer Inst, 1994; 84(13)∶499.
|
18. |
Barbareschi M, Caffo O, Veronese S, et al. bcl2 and p53 expression in nodenegative breast carinoma: a study with longterm followup. Hum Pathol, 1996; 27(11)∶1149.
|
19. |
Sierra A, Castellague X, Tortola S, et al. Apoptosis loss and bcl2 expression: key determinants of lymph nodemetastases in T1 breast cancer. Clin Canc Res, 1996; 2(11)∶1887.
|
20. |
Lee WY, Jin YT, Tzeng CC. Reciprocal expression of bcl2 and p53 in breast ductal carcinoma. Anticancer Res, 1996; 16(50)∶A3007.
|